Refractory Atopic Dermatitis: When to Reassess the Diagnosis
2026-11-18 17:25When Presumed Atopic Dermatitis Does Not Respond: A Diagnostic Workup for Adults
When persistent eczema warrants a closer look at the diagnosis, and which investigations can help identify alternative or coexisting skin conditions.
Persistent dermatitis does not always indicate that atopic dermatitis (AD) requires more intensive treatment. In adults whose symptoms remain uncontrolled despite an appropriately optimized treatment plan, the diagnosis itself may need to be reconsidered.
Allergic contact dermatitis, irritant contact dermatitis, fungal infection and psoriasis can resemble AD or aggravate existing disease. Less common but clinically important conditions, including cutaneous T-cell lymphoma (CTCL), may also present with persistent eczema-like lesions.
A 2026 guideline from the American Academy of Dermatology (AAD) addresses this situation directly. It recommends considering further diagnostic evaluation in adults with presumed AD who do not respond to optimized treatment [1].
The guideline highlights patch testing, skin biopsy and skin scraping as relevant investigations. However, its recommendation is a Good Practice Statement based on indirect evidence and expert consensus. Direct studies comparing diagnostic workup strategies in treatment-resistant adult AD were not available. The guidance therefore supports individualized clinical reassessment rather than a fixed testing protocol.
Before Considering Atopic Dermatitis Treatment-Refractory
An apparent lack of response does not necessarily mean that the disease is resistant to treatment.
The first step is to review whether the original diagnosis and treatment plan were appropriate. Several factors can contribute to persistent symptoms:
The prescribed medication, potency or formulation may not be suitable for the affected area.
Application frequency or technique may be incorrect.
Treatment may have been discontinued too early or used inconsistently.
Adverse effects, cost, access or concerns about medication may affect adherence.
Ongoing exposure to irritants or allergens may continue to trigger inflammation.
Secondary infection or another inflammatory skin condition may be contributing to the presentation.
The expected response period also depends on the treatment used. Topical medication, phototherapy and systemic treatment have different treatment schedules and response timelines.
A patient who has not been able to follow the prescribed regimen presents a different clinical problem from one who has completed appropriate treatment with little improvement.
Once these factors have been reviewed, persistent disease warrants a closer examination of the working diagnosis [1].
Clinical Findings That May Point to Another Diagnosis
Atopic dermatitis is diagnosed primarily through medical history and clinical examination. There is currently no single laboratory biomarker that independently confirms AD or reliably establishes its severity [3].
The distribution, morphology and progression of skin lesions can provide important diagnostic clues.
Adult-onset or atypically distributed eczema
AD can develop during adulthood, so adult onset alone does not exclude the diagnosis. However, new-onset dermatitis should prompt a careful review of potential exposures, particularly when the distribution is unusual.
The face, eyelids, neck, hands and feet deserve particular attention. These areas frequently come into contact with cosmetics, personal care products, occupational substances, gloves, metals, adhesives and topical medications.
Allergic or irritant contact dermatitis may be responsible for the eruption or may coexist with established AD.
Persistent or localized lesions
A localized, asymmetric or sharply demarcated eruption may suggest a contact-related or infectious cause.
For example, dermatitis repeatedly affecting the hands may be associated with occupational exposure to detergents, disinfectants or rubber chemicals. Persistent eyelid dermatitis may warrant investigation of cosmetic, personal care or airborne exposures.
A detailed exposure history can reveal patterns that are not immediately apparent from the skin examination alone.
Lesions with atypical morphology
Several skin disorders share clinical features with eczema. Differences in scaling, border definition, lesion configuration and anatomical distribution help narrow the differential diagnosis.
An annular lesion with peripheral scaling may suggest dermatophyte infection. Well-demarcated plaques with characteristic scaling may indicate psoriasis. Persistent patches or plaques that behave differently from ordinary eczema may require investigation for cutaneous lymphoma, particularly in older adults.
A 2026 review of AD clinical mimics discusses the overlap between AD and inflammatory dermatoses, infections and less common but important alternative diagnoses [2].
Conditions That Can Resemble or Coexist With Atopic Dermatitis
The differential diagnosis should be guided by the patient's clinical presentation rather than by a standard list of tests.
| Possible condition | Clinical clues | Investigation to consider |
|---|---|---|
| Allergic contact dermatitis | Persistent facial, eyelid, hand or foot eczema; worsening after exposure to specific products or materials | Patch testing |
| Irritant contact dermatitis | Burning or stinging after repeated exposure to water, detergents, solvents or friction | Exposure history and clinical assessment |
| Tinea corporis / tinea incognito | Annular or asymmetric lesions, peripheral scale, atypical appearance following corticosteroid use | KOH microscopy and fungal testing |
| Scabies | Intense itching, possible nocturnal worsening, burrows or lesions involving finger webs and wrists | Skin scraping and microscopic examination |
| Psoriasis | Well-defined plaques, thicker scale, extensor involvement or nail changes | Clinical examination; biopsy if uncertain |
| Seborrheic dermatitis | Scalp, eyebrows and nasolabial folds affected, often with greasy scale | Clinical assessment |
| Mycosis fungoides (CTCL) | Persistent or progressive patches or plaques, unusual distribution and poor response to standard eczema treatment | Skin biopsy and clinicopathological correlation |
| Drug eruption | New or worsening rash following medication exposure | Medication history and targeted investigation |
More than one condition may be present. A patient with established AD, for example, can develop allergic contact dermatitis from a topical medication or workplace exposure.
In such cases, treating atopic inflammation alone may not resolve the additional contact-related component.
Allergic contact dermatitis: A particularly relevant consideration
Allergic contact dermatitis (ACD) is a delayed hypersensitivity reaction caused by skin exposure to an allergen. It can closely resemble AD and may occur alongside it.
Common sources include fragrances, preservatives, metals, rubber chemicals, adhesives, cosmetics and topical medications. Occupational exposure may also be relevant for people who regularly handle disinfectants, cleaning agents, industrial materials or protective equipment.
Irritant contact dermatitis (ICD) produces a similar eczematous appearance but has a different mechanism. It results from direct skin barrier damage rather than an allergen-specific immune response.
Patch testing investigates allergic contact hypersensitivity; it does not diagnose irritant contact dermatitis.
A positive patch test also requires clinical interpretation. Sensitization alone does not establish that an allergen is responsible for the current eruption. The clinician must assess whether the patient is exposed to that substance and whether the exposure corresponds to the location and course of the dermatitis.
Infections that can be mistaken for eczema
Tinea incognito is an important consideration when a fungal infection has been treated with topical corticosteroids or other immunomodulating preparations. Treatment may alter the typical appearance of the infection, making it more difficult to recognize.
Scabies can also resemble dermatitis, particularly when scratching and secondary inflammation obscure the original lesions. The distribution of itching, the presence of burrows and symptoms among household contacts may provide useful clues.
Repeatedly escalating anti-inflammatory treatment without investigating a suspected infection can delay appropriate management.
When to consider cutaneous T-cell lymphoma
Early mycosis fungoides, the most common form of cutaneous T-cell lymphoma, can resemble chronic inflammatory dermatitis.
Persistent patches or plaques, unusual clinical progression and poor response to conventional eczema treatment should prompt specialist assessment. Lesions involving relatively protected areas may also raise suspicion.
Age alone is not diagnostic, and most persistent eczema is not lymphoma. However, when the clinical course is atypical, the possibility should not be overlooked.
A skin biopsy is necessary when CTCL is suspected. Clinicopathological correlation is essential, and repeat biopsies may be required when initial findings are inconclusive [2].
Choosing the Appropriate Diagnostic Test
The 2026 AAD guideline identifies patch testing, skin biopsy and skin scraping as particularly relevant investigations in adults with presumed AD that remains uncontrolled despite optimized treatment [1].
Each addresses a different diagnostic question.
1. Patch testing: Is an external allergen contributing to the dermatitis?
Patch testing is the standard diagnostic method for identifying delayed allergic contact hypersensitivity.
It is particularly relevant when adults present with new-onset dermatitis, atypical distribution, persistent hand or facial eczema, or worsening symptoms despite appropriate AD treatment.
Standardized allergen preparations are applied to the skin, usually on the back, under controlled conditions. The patches are removed according to the testing protocol, and reactions are assessed at scheduled readings.
The selection of allergens should reflect the patient's exposure history. A basic screening series may not cover all relevant occupational, cosmetic, personal care or medication-related allergens.
Interpretation is equally important. A positive reaction must be assessed for clinical relevance by considering actual exposure, the location of the eruption and the patient's disease history.
The 2026 European Society of Contact Dermatitis guideline provides updated recommendations on diagnostic patch testing, including test preparation, application, interpretation and special considerations for different patient groups [5].
2. Skin scraping: Could an infection or infestation be responsible?
Skin scraping is useful when fungal infection or scabies is suspected.
For suspected dermatophyte infection, material is collected from an appropriate part of the lesion and examined using potassium hydroxide (KOH) microscopy or other laboratory methods. Fungal microscopy may reveal hyphae supporting the diagnosis.
When scabies is suspected, material collected from an appropriate burrow or papule can be examined for mites, eggs or fecal material.
The choice of sampling site and technique affects diagnostic yield. A negative scraping does not always exclude infection, particularly when the sample is inadequate or clinical suspicion remains high. Repeat sampling, fungal culture or specialist assessment may be appropriate.
Other microbiological investigations may be needed when secondary infection is suspected. Depending on the presentation, bacterial culture or viral PCR may help identify the cause of crusting, pustules, vesicles or erosions [1].
3. Skin biopsy: Does the tissue examination support the working diagnosis?
Skin biopsy is not routinely required to diagnose ordinary atopic dermatitis. It becomes more relevant when the clinical presentation is atypical or when another condition requiring different management is suspected.
Examples include:
Suspected cutaneous T-cell lymphoma.
Possible autoimmune inflammatory skin disease.
Persistent or progressive atypical plaques and patches.
Suspected neoplastic disease.
An unexplained eruption that remains diagnostically uncertain after clinical assessment.
The biopsy site and sampling technique matter. A sample taken from an unsuitable or heavily treated lesion may provide limited information.
Histological findings must be interpreted alongside the patient's history and clinical examination. A nonspecific eczematous pattern does not independently establish a diagnosis of AD.
In selected cases, repeat biopsies or specialist dermatopathology review may be necessary.
Additional investigations should be selected according to clinical findings
The diagnostic workup may extend beyond the three investigations above.
Depending on the suspected condition, clinicians may consider:
Bacterial or fungal culture when secondary infection is suspected.
Viral PCR when herpes simplex or varicella infection is a concern.
Phototesting or photopatch testing for dermatitis predominantly affecting sun-exposed areas.
Autoimmune serology when characteristic clinical or systemic features are present.
Peripheral blood flow cytometry or clonality studies when cutaneous lymphoma or systemic involvement is suspected.
These are targeted investigations, not a routine panel for every adult with persistent eczema. Their value depends on the specific clinical question [1].
Interpreting Results and Planning Follow-Up
A test result needs to be interpreted in the context of the patient's exposure history, clinical findings and response to subsequent management.
Patch testing provides a useful example. A positive reaction must be linked to a relevant exposure before an allergen avoidance plan can be established. Patients may need guidance on identifying the allergen in everyday products, workplace materials or topical preparations.
A 2026 international Delphi consensus involving 18 AD and ACD experts addressed the clinical management of patients with AD undergoing patch testing.
Following four rounds, 21 of 24 clinical management statements and 15 of 18 clinical assessment statements reached consensus. The recommendations included avoiding relevant allergens, using suitable low-reactivity products and reassessing patients at approximately three months using both patient-reported and clinician-reported outcome measures [4].
This follow-up helps assess whether allergen avoidance has made a meaningful difference. Persistent symptoms may indicate incomplete avoidance, another contributing diagnosis or continuing atopic inflammation.
Biopsy and microbiological findings also require clinical correlation. A positive culture may represent colonization rather than active infection, while a negative scraping may reflect sampling limitations.
No individual test result should replace clinical assessment.
What the 2026 AAD Guideline Establishes
The 2026 AAD guideline addresses an important clinical question: how should clinicians approach adults with presumed atopic dermatitis who remain unresponsive despite optimized treatment?
Its Good Practice Statement supports considering further diagnostic workup in these patients [1].
The evidence has limitations. The workgroup used the GRADE framework and reviewed indirect evidence, but direct empirical studies comparing diagnostic workup strategies for treatment-resistant adult AD were lacking. The recommendation therefore reflects expert consensus rather than a universally validated diagnostic algorithm.
There is no requirement for every patient to undergo the same set of investigations. Patch testing is relevant when contact allergy is suspected, skin scraping when infection or infestation is considered, and biopsy when atypical or potentially serious conditions need to be investigated.
For dermatology practice, the guideline reinforces the value of revisiting the working diagnosis when the clinical course does not fit the expected response to treatment. The appropriate next step should be determined by the history, examination and specific diagnostic questions.
Frequently Asked Questions
1. When should atopic dermatitis be reconsidered as a diagnosis?
When presumed AD remains uncontrolled despite an appropriately optimized treatment plan and adequate adherence, clinicians should consider diagnostic reassessment. Atypical distribution, adult-onset disease, persistent localized lesions or an unusual clinical course may provide additional reasons to investigate.
2. What tests are used when atopic dermatitis does not respond to treatment?
The 2026 AAD guideline highlights patch testing, skin biopsy and skin scraping. Additional tests, such as bacterial or fungal cultures, viral PCR, phototesting or targeted blood investigations, may be appropriate depending on the suspected alternative diagnosis.
3. Does every adult with persistent eczema need patch testing?
No. Patch testing is most useful when allergic contact dermatitis is suspected, particularly in patients with persistent facial, eyelid, hand or foot dermatitis, relevant exposure histories or symptoms that remain uncontrolled despite appropriate AD treatment.
4. Can allergic contact dermatitis coexist with atopic dermatitis?
Yes. A patient with established AD can develop contact allergy to fragrances, preservatives, cosmetics, topical medications or occupational substances. Identifying and avoiding the relevant allergen may be necessary alongside treatment for the underlying AD.
5. Can a skin biopsy confirm atopic dermatitis?
Biopsy is not routinely required to diagnose AD. It is more useful when another inflammatory, autoimmune or neoplastic condition is suspected. Histological findings must be interpreted together with clinical features; an eczematous pattern alone does not confirm AD.
6. Can a negative skin scraping rule out fungal infection or scabies?
No. Sampling technique, lesion selection and the amount of diagnostic material obtained affect the result. If clinical suspicion remains high, repeat sampling, additional laboratory testing or specialist assessment may be necessary.
7. What is the difference between allergic and irritant contact dermatitis?
Allergic contact dermatitis is an immune-mediated delayed hypersensitivity reaction to a specific allergen. Irritant contact dermatitis results from direct damage to the skin barrier following exposure to irritating substances or repeated friction. Patch testing is used to investigate allergic contact dermatitis, not irritant contact dermatitis.
References
Sidbury R, Wu PA, Alikhan A, et al. Guidelines for diagnostic testing in adults with presumed atopic dermatitis refractory to treatment. Journal of the American Academy of Dermatology. 2026;95(5):1370.e1–1370.e14. Published online August 31, 2026.
https://doi.org/10.1016/j.jaad.2026.07.039Lawrence CN, Karagounis TK, Cohen DE. Atopic dermatitis reconsidered: Clinical mimics and diagnostic pearls. Journal of the American Academy of Dermatology. 2026;94(5 Suppl):S21–S23.
https://doi.org/10.1016/j.jaad.2025.10.171Zhu J, Abuabara K. Evaluation and work-up of atopic dermatitis. Journal of the American Academy of Dermatology. 2026;94(5 Suppl):S24–S27.
https://doi.org/10.1016/j.jaad.2026.02.094Schlarbaum JP, Warshaw EM, Leshem YA, et al. Assessment and Clinical Management of Patients With Atopic Dermatitis Undergoing Patch Testing: Recommendations From an International Electronic Delphi Consensus. Dermatitis. Published online June 30, 2026.
https://doi.org/10.1177/17103568261457273Uter W, Aerts O, Agner T, et al. European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing—Recommendations on Best Practice (Update 2026). Contact Dermatitis. 2026;95(3):237–275.
https://doi.org/10.1111/cod.70195
Further Clinical Reading
Explore more clinical insights and evidence-based discussions in the KernelMed Dermatology Blog.